X-HW: Funding acquisition, Writing original draft, Writing review & editing
FDA explains that a bulk drug substance used through the 503A pathway generally must meet one of the following conditions: Comply with an applicable United States Pharmacopeia or National Formulary monograph Be a component of a drug product with federal marketing authorization when no applicable monograph exists Appear on the 503A Bulks List when the first two pathways do not apply Additional requirements also apply, including documentation and sourcing requirements for the bulk drug substance
Additionally, the resistance to microbes weakens after 28 days, despite the appearance of the vial being clean
Compromising on Purity: Using cheap, untested peptides from a questionable source is a recipe for disaster
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure
Soda is there and Louis is there